| 生物活性 |
Flavokawain C is an orally active natural chalcone that inhibits the proliferation of multiple cancer cells and induces apoptosis (apoptosis) by upregulating GADD153 in cancer cells, inhibiting the phosphorylation of Akt and JNK, inhibiting early ERK phosphorylation, activating late ERK phosphorylation, activating caspase-related subtypes, inducing PARP-1 cleavage, inducing p21 and p27 upregulation, mutant p53 downregulation, and anti-apoptotic IAP protein downregulation, increasing intracellular ROS levels, and decreasing SOD activity, while downregulating FABP4, inducing cancer cell autophagy (autophagy), and activating the AMPK/mTOR pathway, reducing the expression of glycolysis-related proteins GLUT1 and HK2 to inhibit the glycolytic process in nasopharyngeal carcinoma cells, inhibiting the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and decreasing HSP90B1 expression, inhibiting angiogenesis by reducing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells, increasing intracellular γ-H2AX levels and inhibiting the phosphorylation of FAK, PI3K, and AKT in cells to induce DNA damage, exerting antitumor activity in multiple tumor xenograft mouse models, and is applicable to research related to colorectal cancer, colon adenocarcinoma, Wilms tumor, nasopharyngeal carcinoma, and liver cancer. |
体外研究 (In Vitro) |
Flavokawain C (60 μM; 6-48 h) 上调 HCT 116 细胞中内质网应激标志物 GADD153,抑制 Akt 的磷酸化,抑制早期 ERK 磷酸化、JNK 磷酸化的晚期,激活 ERK 磷酸化的晚期。 Flavokawain C (40-80 μM; 6-72 h) 降低 HT-29 细胞的活力,诱导凋亡形态学及细胞核变化,诱导 DNA 片段化,增加凋亡细胞比例,降低线粒体膜电位,,诱导细胞发生 G2/M 期细胞周期阻滞。 Flavokawain C (40-80 μM; 0-48 h) 在 HT-29 细胞中激活 caspase-3、-8 和 -9,诱导 PARP-1 裂解,诱导不依赖 p53 的 p21 和 p27 上调、突变型 p53 下调、内质网应激标志物 GADD153 上调,以及抗凋亡 IAP 蛋白 (XIAP、c-IAP1、c-IAP2) 下调,提高细胞内的 ROS 水平,降低 SOD 活性。 Flavokawain C (1-15 μM; 24-72 h) 抑制 G401 细胞的活力和增殖,抑制细胞的克隆形成能力,抑制细胞的迁移与侵袭。 Flavokawain C (1-10 μM; 0-24 h) 在 G401 细胞中可调控 EMT 标志物的表达,下调 FABP4,诱导完整的自噬流,并激活 AMPK/mTOR 通路。 Flavokawain C (0.5-4 μM; 48 h) 可抑制人鼻咽癌 HNE1 和 CNE2 细胞的增殖,提高细胞的凋亡率。 Flavokawain C (4 μM; 48 h) 可通过降低细胞外酸化速率、葡萄糖消耗及乳酸生成,降低糖酵解相关蛋白 GLUT1 和 HK2 的表达,抑制人鼻咽癌 HNE1 和 CNE2 细胞的糖酵解过程。 Flavokawain C (4 μM; 48 h) 可抑制人鼻咽癌 HNE1 和 CNE2 细胞中 EGFR/PI3K/Akt/mTOR 信号通路的激活,并降低 HSP90B1 的表达。 Flavokawain C (4 μM; 48 h) 在人鼻咽癌 HNE1 和 CNE2 细胞中可通过损伤人脐静脉内皮细胞 (HUVEC) 的管形成与迁移能力,降低人脐静脉内皮细胞 (HUVECs) 中血管生成蛋白 Ang-1 和 VEGF 的表达来抑制血管生成。 Flavokawain C (48 h) 可选择性抑制 Huh-7、Hep3B 和 HepG2 肝癌细胞的活力,其 IC50 值为 23.42 μM 至 30.71 μM;而对正常 MIHA 肝细胞的毒性较低,IC50 为 53.95 μM。 Flavokawain C (2.0-8.0 μM; 2 weeks) 抑制 Huh-7、Hep3B 和 HepG2 肝癌细胞的集落形成。 Flavokawain C (4.0-16.0 μM; 48 h) 抑制 Huh-7 和 Hep3B 肝癌细胞中的 DNA 复制,诱导细胞发生凋亡,下调细胞中抗凋亡蛋白 Bcl2 的表达,上调促凋亡蛋白 Bax 的表达,通过降低 Bcl2/Bax 比值来促进细胞凋亡。 Flavokawain C (4.0-16.0 μM; 48 h) 提高 Huh-7 和 Hep3B 细胞中 DNA 损伤应答标志物 γ-H2AX 的水平,抑制细胞中 FAK、PI3K 及 AKT 的磷酸化,诱导细胞发生 DNA 损伤。 Flavokawain C (4.0-16.0 μM; 48 h) 降低 Huh-7 和 Hep3B 细胞的细胞外基质黏附性,抑制细胞的迁移。
Western Blot Analysis
| Cell Line: |
HCT 116 human colon carcinoma cells |
| Concentration: |
60 μM |
| Incubation Time: |
6, 12, 18, 24, 48 h |
| Result: |
Induced time-dependent upregulation of GADD153 protein levels. Showed no GADD153 expression was detected in untreated control cells.\nCaused a transient increase in phosphorylated Akt levels at 6 hours. Induced time-dependent decrease in phosphorylated Akt levels through 48 hours. Showed no significant changes in total Akt protein levels were observed.\nCaused time-dependent decreases in phosphorylated ERK levels at 6, 12, and 18 hours. Induced dramatic increases in phosphorylated ERK levels at 24 and 48 hours. Showed total ERK levels remained unchanged. Caused small reductions in phosphorylated JNK levels at 24 and 48 hours. Showed no significant changes in total JNK, phosphorylated p38, or total p38 levels. |
Cell Viability Assay
| Cell Line: |
human colon adenocarcinoma HT-29 cells |
| Concentration: |
40, 60, 80 μM |
| Incubation Time: |
0, 6, 12, 24, 48, 72 h |
| Result: |
Reduced HT-29 cell viability in a dose- and time-dependent manner. Decreased cell viability from 644.51% (control) to 185.17%, 111.81%, and 104.94% at 40, 60, and 80 μM respectively after 72 h. Showed comparable inhibitory effect between 60 and 80 μM. |
Apoptosis Analysis
| Cell Line: |
human colon adenocarcinoma HT-29 cells |
| Concentration: |
40, 60, 80 μM |
| Incubation Time: |
48 h |
| Result: |
Induced dose-dependent apoptotic morphological changes, including cell shrinkage, surface blebbing, cytoplasmic vacuolation, chromatin condensation/fragmentation, and late apoptotic cells (pink fluorescence from propidium iodide staining).\nCaused a concentration-dependent increase in DNA fragmentation. Increased TUNEL-positive cells to 11.6% at 80 μM relative to control. |
Apoptosis Analysis
| Cell Line: |
human colon adenocarcinoma HT-29 cells |
| Concentration: |
40-80 μM |
| Incubation Time: |
24-48 h |
| Result: |
Caused a dose- and time-dependent increase in Annexin V-FITC-positive apoptotic cells. |
Cell Cycle Analysis
| Cell Line: |
human colon adenocarcinoma HT-29 cells |
| Concentration: |
40-80 μM |
| Incubation Time: |
24-48 h |
| Result: |
At 24 h, dose-dependently increased G2/M phase cell population (with a small G1 phase accumulation) and decreased S phase population. At 48 h, caused a marked dose-dependent increase in G2/M phase cell population, with the highest increase at 80 μM. |
Cell Autophagy Assay
| Cell Line: |
G401 nephroblastoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
12 h |
| Result: |
Increased the number of both yellow (autophagosomes) and red (autolysosomes) puncta per cell compared to control, indicating enhanced autophagic initiation and maturation. |
Immunofluorescence
| Cell Line: |
Huh-7, Hep3B |
| Concentration: |
4.0 μM, 8.0 μM, 16.0 μM |
| Incubation Time: |
48 h |
| Result: |
Dose-dependently increased the number of 53BP1 foci (a marker of DNA damage response) in both cell lines. Increased average 53BP1 foci per cell to >15 in both cell lines at 16.0 μM, compared to ~1.5 foci per cell in untreated controls. |
|
体内研究 (In Vivo) |
Flavokawain C (3 mg/kg;腹腔注射;每周 3 次;持续 4 周) 可抑制 BALB/c 裸鼠体内肾母细胞瘤异种移植物的生长,显著降低肿瘤体积与重量,而该效应可被 FABP4 过表达部分逆转。 Flavokawain C (3 mg/kg;腹腔注射;4 周 (皮下肿瘤模型);8 周 (肝转移模型)) 可在体内减小鼻咽癌皮下移植瘤的体积与重量,抑制肝转移,并下调糖酵解、血管生成及 EGFR/PI3K/Akt/mTOR 通路的激活;HSP90B1 敲低可增强其作用,而 HSP90B1 过表达则会逆转该作用。 Flavokawain C (16 mg/kg;腹腔注射;每日一次;连续 14 天) 可通过抑制肿瘤细胞增殖并诱导 DNA 损伤,显著抑制裸鼠体内 Huh-7 肝癌异种移植物的生长,且不会导致明显的体重下降。 Flavokawain C (1-3 mg/kg;腹腔注射;每周 3 次;持续 19 天) 可剂量依赖性地抑制 BALB/c 裸鼠体内 HCT 116 结肠癌异种移植物的生长,其中 3 mg/kg 剂量的肿瘤体积抑制率最高可达 52.17%;其作用机制为诱导细胞凋亡并降低细胞增殖活性,且不会引发显著的器官毒性。
| Animal Model: |
BALB/c nude (5-week-old male, weight range 19.0g to 22.3g at euthanasia, subcutaneous nephroblastoma xenograft model) |
| Dosage: |
3 mg/kg |
| Administration: |
i.p.; thrice weekly; 4 weeks |
| Result: |
Significantly reduced tumor volume and tumor weight compared to the control group. Reduced expression of Ki67, FABP4, and Vimentin in tumor tissues. Increased expression of E-cadherin in tumor tissues. Induced loose tumor structure and increased inflammatory cell infiltration in tumor samples. Had its tumor growth inhibition effect partially reversed by FABP4 overexpression. |
| Animal Model: |
BALB/C nude (male, 5-6 weeks old) |
| Dosage: |
3 mg/kg |
| Administration: |
i.p.; 4 weeks (subcutaneous tumor model); 8 weeks (liver metastasis model) |
| Result: |
Reduced subcutaneous tumor volume and weight compared to vehicle control. Downregulated the expression of HSP90B1, GLUT1, HK2, Ang-1, and VEGF in tumor tissues. Inhibited the phosphorylation of EGFR, PI3K, Akt, and mTOR in tumor tissues. Inhibited liver metastasis of NPC tumors, as measured by reduced bioluminescence signal from luciferase-expressing tumor cells. Enhanced inhibitory effect on tumor growth and pathway suppression was observed with HSP90B1 knockdown. Reversed inhibitory effect on tumor growth and pathway suppression was observed with HSP90B1 overexpression. |
| Animal Model: |
BALB/c nude mice (6-week-old) |
| Dosage: |
16 mg/kg |
| Administration: |
i.p.; daily; 14 days |
| Result: |
Significantly reduced tumor growth rate, final tumor volume, and final tumor weight relative to controls. Caused no significant changes in mouse body weight during treatment. Induced cytoplasmic-nuclear separation and nuclear fragmentation (cell death) in tumor tissues via H&E staining. Reduced Ki67 (proliferation marker) levels in treated tumor tissues. Increased γ-H2AX (DNA damage marker) levels in treated tumor tissues. |
| Animal Model: |
BALB/c nude (female, 6 weeks old) |
| Dosage: |
1 mg/kg; 3 mg/kg |
| Administration: |
i.p.; thrice weekly; 19 days |
| Result: |
Reduced final mean tumor volume to 658.19 mm3 (600% growth from initial 84.48 mm3) with 18.73-23.99% tumor volume inhibition (%T/C) over days 3-19 at 1 mg/kg. Reduced final mean tumor volume to 411.31 mm3 (300% growth from initial 86.56 mm3) with 23.43-52.17% tumor volume inhibition (%T/C) over days 3-19 at 3 mg/kg. Increased tumor necrotic area significantly (p < 0.05 vs control) at 3 mg/kg. Increased TUNEL-positive cells significantly (p < 0.05 vs control) at 3 mg/kg. Increased cleaved caspase-3 immunoreactivity score significantly (p < 0.05 vs control) at 3 mg/kg. Decreased Ki67 immunoreactivity score significantly (p < 0.05 vs control) at 3 mg/kg. Up-regulated Ig mu chain C region (secreted form) and down-regulated GRP78, hemopexin, kininogen-1, and apolipoprotein E compared to vehicle controls, with levels returning to near normal ranges at 3 mg/kg. Caused no significant body weight loss in either dose group; kept serum liver (AST, ALT, ALP) and kidney (creatine, urea) function parameters within normal limits, with only mild urea elevation in the 1 mg/kg group; caused no pathological damage to major organs (heart, spleen, liver, lungs, kidneys). |
|
| 性状 |
固体 |
| 颜色 |
Light yellow to orange |